Stock Scorecard
Stock Summary for Kinnate Biopharma Inc (KNTE) - $2.66 as of 3/27/2024 9:06:54 PM EST
Total Score
12 out of 29
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for KNTE
Positive earnings growth | |
P/E ratio less than Industry P/E Ratio | |
P/E ratio less than Sector P/E Ratio | |
P/E ratio that is half the growth rate (or less) | |
Positive net cash position the past year and most recent quarter | |
Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
Positive net income past year and 12 trailing months | |
Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for KNTE
Revenue growing by at least 20% average per year over the last 5 years | |
Market Capitalization under 2 billion | |
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for KNTE
Declared an ex-dividend date | |
Forward annual dividend rate greater than 2 | |
Positive net cash position the past year and most recent quarter | |
Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
Current ratio most recent quarter greater than 2 |
Bonus Criteria for KNTE
P/E ratio less than five-year Average P/E ratio | |
Last Price to 52 Week Low Ratio Less Than 1 | |
Total Cash Per Share > Last Day Price | |
P/S Ratio < 1 | |
P/B Ratio < 1 |
Latest News for for KNTE
Financial Details for KNTE
Company Overview |
|
---|---|
Ticker | KNTE |
Company Name | Kinnate Biopharma Inc |
Country | USA |
Description | Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers. The company is headquartered in San Diego, California. |
Sector Name | LIFE SCIENCES |
Industry Name | PHARMACEUTICAL PREPARATIONS |
Most Recent Quarter | 9/30/2023 |
Next Earnings Date | 5/9/2024 |
Stock Price History |
|
Last Day Price | 2.66 |
Last Day Price Updated | 3/27/2024 9:06:54 PM EST |
Last Day Volume | 472,024 |
Average Daily Volume | 507,543 |
52-Week High | 7.18 |
52-Week Low | 1.04 |
Last Price to 52 Week Low | 155.77% |
Valuation Measures |
|
Trailing PE | N/A |
Industry PE | 100.07 |
Sector PE | 60.76 |
5-Year Average PE | -4.02 |
Free Cash Flow Ratio | 0.75 |
Industry Free Cash Flow Ratio | 12.70 |
Sector Free Cash Flow Ratio | 31.04 |
Current Ratio Most Recent Quarter | 10.80 |
Total Cash Per Share | 3.55 |
Book Value Per Share Most Recent Quarter | 3.66 |
Price to Book Ratio | 0.73 |
Industry Price to Book Ratio | 5.57 |
Sector Price to Book Ratio | 21.66 |
Price to Sales Ratio Twelve Trailing Months | 0.00 |
Industry Price to Sales Ratio Twelve Trailing Months | 13.94 |
Sector Price to Sales Ratio Twelve Trailing Months | 8.77 |
Share Statistics |
|
Total Shares Outstanding | 47,166,400 |
Market Capitalization | 125,462,624 |
Institutional Ownership | N/A |
Dividends |
|
Ex-Dividend Date | N/A |
Last Dividend Amount | 0.00 |
Current Dividend Amount | 0.00 |
Dividend Aristocrat? | False |
Trailing Annual Dividend Rate | 0.00 |
Trailing Annual Dividend Yield | 0.00% |
Forward Annual Dividend Rate | 0.00 |
Forward Annual Dividend Yield | 0.00% |
5-Year Dividend Payments Count | 0 |
3-Year Average Dividend Yield | 0.00% |
5-Year Average Dividend Yield | 0.00% |
1-Year Dividend Growth Rate Percentage | 0.00% |
3-Year Dividend Growth Rate Percentage | 0.00% |
5-Year Dividend Growth Rate Percentage | 0.00% |
All-Time Dividend Growth Rate Percentage | 0.00% |
Dividend Payout Ratio | N/A |
Income Statement |
|
Quarterly Earnings Growth YOY | 0.00% |
Annual Earnings Growth | -29.53% |
Reported EPS 12 Trailing Months | -2.78 |
Reported EPS Past Year | -2.06 |
Reported EPS Prior Year | -2.65 |
Net Income Twelve Trailing Months | -127,154,000 |
Net Income Past Year | -116,271,000 |
Net Income Prior Year | -89,763,000 |
Quarterly Revenue Growth YOY | 0.00% |
5-Year Revenue Growth | 0.00% |
Balance Sheet |
|
Total Cash Most Recent Quarter | 167,576,000 |
Total Cash Past Year | 201,475,000 |
Total Cash Prior Year | 219,458,000 |
Net Cash Position Most Recent Quarter | 167,176,000 |
Net Cash Position Past Year | 201,075,000 |
Long Term Debt Past Year | 400,000 |
Long Term Debt Prior Year | 400,000 |
Total Debt Most Recent Quarter | 400,000 |
Equity to Debt Ratio Past Year | 1.00 |
Equity to Debt Ratio Most Recent Quarter | 1.00 |
Total Stockholder Equity Past Year | 223,468,000 |
Total Stockholder Equity Prior Year | 319,477,000 |
Total Stockholder Equity Most Recent Quarter | 172,420,000 |
Options |
|
Put/Call Ratio | 0.00 |
Has Options | Options Chain |
Liquidity Rating | |
Technical Analysis |
|
Yahoo Finance Chart | Yahoo Finance Chart |
MACD | 0.05 |
MACD Signal | 0.05 |
20-Day Bollinger Lower Band | 2.18 |
20-Day Bollinger Middle Band | 2.43 |
20-Day Bollinger Upper Band | 2.69 |
Beta | 1.34 |
RSI | 66.62 |
50-Day SMA | 2.54 |
200-Day SMA | 0.00 |
System |
|
Modified | 3/26/2024 11:43:44 PM EST |